SEPN vs TECH: fair value comparison
Septerna, Inc. and Bio-Techne Corporation · Updated 2026-10-19
SEPN has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, TECH currently ranks higher by quality score.
| SEPN | TECH | |
|---|---|---|
| Verdict | No estimate yet | Undervalued |
| Last price | $36.35 | $72.46 |
| 12-month range | $18.10–$48.19 | $43.30–$72.61 |
| Rank by discount to fair value | — | #42 of 108 Healthcare |
| Rank by quality score | #21 of 301 Healthcare | #20 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Stable | Stable |
| Revenue growth | — | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Uptrend |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: SEPN fair value analysis · TECH fair value analysis